1686. 48-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1
Session: Oral Abstract Session: HIV: Modern ART
Friday, October 6, 2017: 2:26 PM
Room: 07AB


Background: Management of multi-drug resistant (MDR) HIV-1 remains a challenge. The advent of antiretroviral (ARVs) with novel mechanisms of action are needed to expand therapeutic options for MDR patients. Ibalizumab (IBA) is a humanized monoclonal antibody with a unique binding specificity to the CD4 domain 2, allowing it to block viral entry into host cells without CD4 depletion. Patients completing the 24-week Phase 3 study (TMB-301) continued treatment in study TMB-311. Here, we report the durable efficacy and long-term safety of IBA with an optimized background regimen (OBR) through 48 weeks of treatment.

Methods: TMB-301 was an open-label study investigating the antiviral activity and safety of IBA plus OBR in highly treatment-experienced patients with MDR HIV-1. Patients received an intravenous loading dose of 2000 mg followed by 800 mg doses every 2 weeks for 24 weeks. 7 days after loading dose, an OBR was added with at least 1 additional sensitive agent throughout the study. Following completion of the 24-week TMB-301 study, patients continued to receive IBA at 800 mg every 2 weeks under TMB-311 for up to 48 weeks. Safety and efficacy were assessed until 48 weeks.

Results: A total of 31 patients enrolled in TMB-301 completed the 24-week treatment period. Of 31 patients, 27 entered study TMB-311. These patients were highly resistant patients - 59% and 33% of patients had exhausted ≥3 and ≥4 ARV classes, respectively, and 7% of patients had HIV-1 resistant to all approved ARVs.

IBA plus OBR was well tolerated. Of the 27 patients, 24 (89%) continued to receive treatment until Week 48. The 3 patients discontinued early due to non IBA-related reasons. No new or unexpected safety concerns emerged between Week 24 and 48.

The potent suppression of viremia observed Week 24 was sustained through Week 48. Median viral load (VL) reduction from BL was 2.5log10 at both Week 24 and 48. 16 of 27 patients (59%) had VL <50 copies/mL and 17 (63%) patients had VL <200 copies/mL. All 15 patients with VL <50 copies/mL at Week 24 maintained viral suppression to Week 48.



Conclusion: IBA plus OBR continued to achieve high rates of virologic suppression through Week 48. The results support the durable efficacy and long-term safety of IBA in highly treatment-experienced MDR patients and offer a valuable treatment option for patients.


Brinda Emu, MD1, W Jeffery Fessel, MD2, Shannon Schrader, MD3, Princy N. Kumar, MD, FIDSA4, Gary Richmond, MD5, Sandra Win, MD, MS6, Steven Weinheimer, PhD7, Christian Marsolais, PhD8 and Stanley Lewis, MD7, (1)Yale School of Medicine, New Haven, CT, (2)Kaiser Foundation Research Insitute, San Francisco, CA, (3)Research Access Network, Houston, TX, (4)Georgetown University Medical Center, Washington, DC, (5)Gary Richmond, PA, Fort Lauderdale, FL, (6)eStudy Site, San Francisco, CA, (7)TaiMed Biologics USA, Irvine, CA, (8)Theratechnologies Inc, Montreal, QC, Canada


B. Emu, Theratechnologies, 3VBioscences, Achaogen, MedImmune, Genentech: Consultant and Shareholder , Salary

W. J. Fessel, None

S. Schrader, None

P. N. Kumar, TaiMed: Advisory Board and Investigator , Consulting fee and Grant recipient

G. Richmond, TaiMed: Investigator , Research support

S. Win, None

S. Weinheimer, TaiMed: Employee , Salary

C. Marsolais, TaiMed: Commercial partner , Salary and Salary from Theratechnologies, commercial partner

S. Lewis, TaiMed: Employee , Salary and Salary from Theratechnologies, commercial partner

See more of: HIV: Modern ART
See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.